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Pertussis is an endemic respiratory disease caused by the bacterium Bordetella pertussis. Globally, there are about 24 million cases and 160 000 deaths from per-
tussis in children less than 5 years of age every year.1 Canada 
introduced whole-cell pertussis vaccine into the routine vac-
cination schedule in 1943 and replaced it with acellular per-
tussis vaccine, which has a better safety profile, in 1997–
1998. In Canada, pertussis vaccines are given to all children 
at ages 2, 4, 6 and 18  months, 4–6  years and 10–15  years 
(Quebec: 2, 4 and 12 mo, and 4–6 yr) (Appendix 1, Supple-
mental Table S1, available at www.cmajopen.ca/content/8/ 
4/E651/suppl/DC1).2
During 2012–2015, pertussis incidence increased mark-
edly in Canada, to 3.6–13.4/100 000 per year,3 and frequent 
outbreaks continue to occur globally.4–10 Young infants have 
the highest burden of pertussis in Canada.11 During 1999–
2015, 76% of 1402 children admitted to hospital with per-
tussis were infants aged 3 months or less. Infants aged less 
than 2 months had the highest annual incidence of hospital 
admission and intensive care unit admission (116 and 33 per 
100 000, respectively). As current infant vaccination pro-
grams starting at age 2 months cannot protect these young-
est, most vulnerable infants, pertussis vaccination during 
each pregnancy is recommended in Canada, as well as in 
other countries.12,13
In February 2018, the Canadian National Advisory Com-
mittee on Immunization recommended that all pregnant 
women receive pertussis vaccine (in the form of tetanus–
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structural uncertainty assessed through scenario analyses. The analysis adopted an acquisition price of Tdap vaccine of $12.50, with 
scenario analysis conducted to identify the threshold price for vaccination to be cost-effective.
Results: In the base-case scenario, for every 1000 pregnant women vaccinated, the program would lead to a gain of 0.3 QALYs, 
occurring solely in infants, at an increased total cost of $12 987, or $44 301 per QALY gained. Based on a threshold of $50 000 per 
QALY gained, vaccination would have been cost-effective in 6 of the 10 years included in the model (range of incremental costs 
$20 463–$100 348 per QALY gained). The threshold cost for Tdap vaccine to be cost-effective over the 10-year horizon was $14.03.
Interpretation: Based on a threshold of $50 000 per QALY gained, vaccination against pertussis in pregnancy would be cost-
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diphtheria–acellular pertussis [Tdap] vaccine) in every preg-
nancy, ideally at 27–32  weeks’ gestation.12 Vaccination 
against pertussis in pregnancy has proved to be highly 
(nearly 90%) effective in preventing pertussis disease in 
infants aged less than 3 months in the United Kingdom and 
United States,14–16 and in decreasing the risk of hospital 
admission, intensive care unit admission and hospital length 
of stay.17
Assuming that vaccination against pertussis in pregnancy is 
90% effective in preventing hospital admission for pertussis 
among infants aged less than 3 months, admission of about 
825  infants with pertussis to tertiary care centres in Canada 
could have been prevented via maternal vaccination during 
1999–2015. However, the cost-effectiveness of this strategy is 
an important consideration. The objective of the present 
study was to assess the cost-effectiveness of vaccination in 
pregnancy with Tdap vaccine in Canada.
Methods
Design
The decision problem or research question was whether vac-
cination against pertussis in pregnancy should be funded by 
the relevant public health care payer. To answer this question, 
we conducted a cost-utility analysis that compared pertussis 
vaccination to no vaccination. The analysis was conducted 
over a lifetime horizon from a health care payer perspective 
(incorporating the lifetime costs and effects of the vaccination 
and subsequent events). Our analysis corresponded with the 
2017 Canadian guidelines for economic evaluation from the 
Canadian Agency for Drugs and Technologies in Health.18
Model structure
We developed a de novo model that included decision tree 
and Markov model elements to estimate the long-term cost 
and quality-adjusted life-years (QALYs) associated with vac-
cination versus no vaccination for both infants and pregnant 
women (Figure 1; Appendix 2, available at www.cmajopen.
ca/content/8/4/E651/suppl/DC1).19 For infants, the short-
term decision tree estimated the following outcomes: pro-
portion who, by 12 months of age, would have had no per-
tussis, mild pertussis (no hospital admission) or pertussis 
requiring hospital admission (with and without encephalitis 
and chronic encephalitis), or would have died. For pregnant 
women, a decision tree estimated the following outcomes: 
proportion with no pertussis, mild pertussis, severe pertussis 
(cough illness with apnea, cyanosis, vomiting or urinary 
incontinence), pneumonia without hospital admission or 
pneumonia with hospital admission, or who died. For both 
infants and women, for each of the outcomes, we created a 
Markov model with a 1-year cycle and a lifetime horizon (up 
to age 110) with the states of alive and dead.
Model parameter values
To select the parameters used in our model, we conducted a 
targeted search of the English-language literature on costs 
and utilities to identify the most pertinent recent data appli-
cable to the Canadian context (Appendix 1, Supplemental 
Table S2; Appendix 2). Data required to facilitate estimation 
of transition probabilities included the probability of pertus-
sis in infants and adults, the severity of pertussis cases and 
the duration of symptoms, the effectiveness of vaccination, 
and the incidence of vaccination-related adverse events and 
their duration. We divided adverse events following vaccina-
tion into local (defined as a sore upper arm that is slightly 
red, swollen and tender) and systemic (defined as a low-
grade fever, headache, body ache and decreased energy).
In addition, costs and utility values for each potential out-
come were required. We obtained these from the literature 
through a detailed targeted review and selected them based 
on their fitness for purpose (i.e.,  relevance to the decision 
problem), credibility and consistency. We assessed fitness for 
purpose based on the contemporaneous nature of the data 
and the relevance to the specific outcomes. We assessed cred-
ibility based on the appropriateness of the methodology 
adopted to derive the data estimates, and assessed consistency 
by adopting parameter values from the literature using simi-
lar methods and approaches.
As pertussis is a cyclical disease, with peaks occurring every 
3–4 years asynchronously across Canada,20 we used epidemio-
logic data relating to infant infection for 2006–2015.21
Base case
The model estimated 71 cases of pertussis disease per 100 000 
among all infants less than 1 year of age, with 68% of cases in 
those aged less than 2 months and 18% in those aged 
2–4  months.21 This would translate to about 284  cases per 
year among all infants aged less than 1  year (assuming an 
annual birth cohort of 400 00022), including 192 cases in those 
aged less than 2 months and 52 cases in those 2–4 months of 
age. High rates of hospital admission occur in this age group 
(estimated at 87% for infants < 2 mo of age and 84% for those 
aged 2–4 mo).6 It was estimated that, among all infants less 
than 12  months of age admitted to hospital, death would 
occur in 0.8% and encephalitis in 0.5%, with chronic enceph-
alitis developing in 33% of those with acute encephalitis.2,23
The model estimated 0.6  cases per 100 000  pregnant 
women per year, with pneumonia requiring hospital admis-
sion occurring in 1 in every 10 million. Overall, 31% of cases 
in pregnant women were assumed to be mild and 67% severe, 
with severity unknown in 2%.24
Symptom duration was estimated at 93 days for pregnant 
women and 75 days for infants.25
Based on a cohort study by Amirthalingam and colleagues26 
with a sample size of 72 781, the model estimated overall vac-
cine effectiveness (in infants and pregnant women) to be 91% 
(95% confidence interval [CI] 0.88–0.94) against pertussis and 
95% (95% CI 0.79–1.00) against death from pertussis. A 
recent systematic review27 showed that vaccination effective-
ness in preventing pertussis in infants of vaccinated women 
ranged from 69% in a small (n = 96) case–control study28 to 
91% in 3 other studies.16,26,29 The authors of the systematic 
review found only 1  study with an estimate of vaccination 
effectiveness in reducing deaths from pertussis.26
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Figure 1: Markov models to estimate the long-term cost and quality-adjusted life-years associated with vaccination with tetanus–diphtheria–
acellular pertussis vaccine v. no vaccination in pregnancy. (A) Infants. (B) Women.
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The model estimated local adverse events following vacci-
nation to occur at a prevalence of 15% and a time to full 
recovery of 7 days.30,31 Systemic reactions were estimated to 
occur in 6% of cases, with a time to full recovery of 7 days.30,31 
Anaphylaxis was estimated to occur once per 200 000 doses, 
with a time to full recovery of 2 days.31,32
Statistical analysis
Long-term outcomes were discounted at a rate of 1.5% per 
annum, with costs expressed in 2019 Canadian dollars. In the 
base-case scenario, we obtained expected values of costs and 
QALYs through probabilistic analysis. We obtained values for 
all uncertain data through random sampling from their proba-
bility distributions and, for the epidemiologic data, the year 
from which the data were taken, also drawn randomly.
We assessed methodologic and structural uncertainty 
through scenario analyses. We conducted analyses using epi-
demiologic data specific to each year. In addition, we con-
ducted analysis using different discount rates (0% and 3%), as 
well as a time horizon of 50 years for estimating long-term 
costs and QALYs.
As the acquisition cost of Tdap vaccine in this context is 
confidential and thus was uncertain, analysis adopted a price 
of $12.50 (plus $4.50 in administration costs) for illustrative 
purposes, with scenario analysis conducted to identify the 
threshold price for vaccination to be cost-effective. Because 
vaccination would be given at routine care, the model 
assumed no additional program costs.
Ethics approval
Ethics approval was not required because of the study type.
Results
In the base-case scenario, with epidemiologic data across the 
period from 2006 to 2015, the Tdap vaccination program 
would cost an additional $17 000 per 1000 pregnant women 
vaccinated ($17 per woman) but would reduce the costs of 
treatment for pertussis per 1000  pregnant women vacci-
nated, for both infants (by $12 987) and women (by $1.00). 
The program would lead to a gain of 0.3  QALYs per 
1000  pregnant women vaccinated, occurring solely in 
infants. This would lead to an incremental cost per QALY 
gained of $44 301 (Table 1).
At a threshold of $50 000 per QALY gained, the probabil-
ity that vaccination would be cost-effective is 52% (Figure 2). 
At a threshold of $100 000 per QALY gained, the probability 
that it would be cost-effective is 84%. If the acquisition cost of 
Tdap vaccine were $14.03, the incremental cost per QALY 
gained from vaccination would be $50 000 (Figure 3). Thus, if 
the willingness to pay per QALY gained were $50 000 and the 
cost of Tdap vaccine were no more than $14.03, vaccination 
would be cost-effective.
Scenario analyses
Analysis by each year of epidemiologic data showed that the 
estimates are highly dependent on annual disease burden, 
which fluctuates owing to the natural cycling of disease 
(Table 2). Based on a threshold of $50 000 per QALY gained, 
vaccination would have been cost-effective in 6 of the 10 years 
included in the model (range $20 463 in the year with the 
highest disease burden to $100 348 in the year with the lowest 
disease burden). The probability that vaccination would be 
cost-effective (assuming a threshold of $50 000 per QALY 
gained) ranged from a high of greater than 99% to a low of 
less than 1% (Figure 3).
Because vaccination during pregnancy is expected to be 
implemented more widely in the future, we applied a discount 
rate, which resulted in incremental costs of $29 365 for a rate 
of 0% to $75 872 for a rate of 5% (Table 2). Adopting a 
reduced time horizon of 50  years for estimating long-term 
costs and QALYs led to an increase in the incremental cost 
per QALY to $54 398.
We performed a scenario analysis using the lower estimate 
of vaccination effectiveness (69% reduction in pertussis cases), 
from the case–control study,28 and found that vaccination 
would not be cost-effective under this scenario (incremental 
cost $55 031)  (Table 2).
Interpretation
Our cost-effectiveness analysis showed that vaccination in 
pregnancy with Tdap vaccine would be cost-effective in 
Canada if the acquisition cost of the vaccine alone were no 
more than $14.03 per dose at a threshold of $50 000 per 
QALY gained. This is based on national data and disease 
Table 1: Cost-effectiveness per 1000 pregnant women of 
vaccination in pregnancy with tetanus–diphtheria–acellular 
pertussis vaccine
Variable Vaccine No vaccine Incremental
Cost, $*
    Vaccine 17 000 0 17 000
Treatment of pertussis 
in infant
404 4416 –4012
Treatment of pertussis 
and adverse events in 
woman
0.1 1 –1
    Total 17 404 4417 12 987
No. of pertussis cases
    Infants 0.065 0.710 –0.645
    Women 0.006 0.001 –0.005
QALYs
    Infants 41 020.4 41 020.1 0.3
    Women 31 966.0 31 966.0 0.0
    Total 73 016.4 73 016.1 0.3
Incremental cost per 
QALY gained, $*
– – 44 301
Note: QALY: quality-adjusted life-year.
*In 2019 Canadian dollars.
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Figure 2: Cost-effectiveness acceptability curve for pertussis vaccination during pregnancy in Canada. Costs are presented in 2019 Canadian 
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Figure 3: Estimated incremental cost per quality-adjusted life-year (QALY) gained by acquisition cost of pertussis vaccine. Costs are presented 
in 2019 Canadian dollars.
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burden estimates over a 10-year period that account for the 
natural annual fluctuation in pertussis incidence. Our anal-
ysis highlights that cost-effectiveness is somewhat depen-
dent on annual disease incidence, with the threshold of 
$50 000 per QALY gained being reached in 6 of the 
10  years. This cost-effectiveness modelling is comprehen-
sive, as it considered the age-specific burden of disease, 
temporal changes in disease incidence, severe outcomes, 
vaccine effectiveness, adverse events following vaccination, 
and costs of both the vaccine program and health care 
treatment related to pertussis.
Our results are similar to those found in the US, Brazil and 
the Netherlands, although any comparisons with other set-
tings should be interpreted with caution, as results of cost-
effectiveness analyses are highly context dependent.33–35 Based 
on our base-case scenario, vaccination with Tdap in preg-
nancy in Canada would lead to an incremental cost of $44 301 
per QALY gained and would have been cost-effective in 6 of 
the 10  years studied. Similarly, the incidence of pertussis 
influenced cost-effectiveness estimates in England, where the 
strategy of pertussis vaccination in pregnancy was estimated to 
achieve an incremental cost of £16 856–£42 070 per QALY 
gained.36 The highest gain was predicted to be achieved at 
£16 856 in the year with the highest incidence.
The results of cost-effectiveness analyses are affected by 
the cost per vaccination, which directly affects costs per 
QALY gained. Lower-cost pertussis vaccines may be cost-
effective even in years with lower rates of pertussis incidence 
if they can display similar efficacy. In our study, the vaccina-
tion cost was $17, which gave an incremental cost of $44 301 
per QALY gained. In a US study with a high vaccine cost 
(US$57.60), the incremental cost per QALY gained was much 
higher, US$414 523.37 Other investigators have estimated the 
cost of vaccine to be in the range of US$14.6–US$57.60 
(Can$19.60–$77.20),33–39 with cost-effectiveness ranging 
depending on disease incidence.
Because pertussis vaccination is recommended during each 
pregnancy,12,13 our cost-effectiveness analysis would still be 
valid for subsequent pregnancies. If this recommendation 
changes in the future, the cost-effectiveness analysis should be 
modified accordingly. If modulation of infants’ immune 
responses is found to be clinically significant, this effect 
should be modelled in future cost-effectiveness analyses, as it 
may decrease the cost-effectiveness of a maternal vaccination 
strategy if additional infant booster doses are required. 
Finally, our cost-effectiveness analysis is based on data pub-
lished between 2006 and 2015; thus, this analysis should be 
updated as more data are collected and published.
Table 2: Scenario analyses relating to year of epidemiologic data, discount rate, time horizon and source of vaccine effectiveness
Scenario
Total costs per 1000 pregnant women, $* Total QALYs per 1000 pregnant women Incremental cost of 
vaccination per QALY 
gained, $*†Vaccine No vaccine Vaccine No vaccine
Base case 17 404 4417 73 016.4 73 016.1 44 729
Year
    2006 17 579 6339 73 015.4 73 015.0 26 660
    2007 17 464 5089 73 017.2 73,016.8 37 024
    2008 17 525 5750 73,017.1 73 016.7 30 961
    2009 17 437 4766 73 015.7 73 015.4 40 811
    2010 17 210 2297 73 016.8 73 016.6 100 348
    2011 17 224 2448 73 015.7 73 015.5 93 145
    2012 17 691 7551 73 015.6 73 015.1 20 463
    2013 17 248 2703 73 016.8 73 016.6 82 554
    2014 17 244 2672 73 016.2 73 016.0 83 076
    2015 17 415 4533 73 017.6 73 017.3 42 772
Discount rate, %
    0 17 413 4521 117 249.1 117 248.7 29 365
    3 17 397 4349 50 463.6 50 463.4 59 594
    5 17 394 4295 34 738.1 34 737.9 75 872
50-yr time horizon 17 402 4395 60 992.1 60 991.9 54 398
Vaccine effectiveness28 
(n = 96)
18 569 4409 73 017.8 73 017.5 55 031
Note: QALY = quality-adjusted life-year.
*In 2019 Canadian dollars.
†Bolded values represent scenarios under which vaccination during pregnancy would be cost-effective assuming a willingness to pay per QALY gained of $50 000.
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Limitations
Our study has several limitations. Our search for model 
parameters was limited to the English-language literature; 
thus, our results should be interpreted with caution in prov-
inces and territories where data are published in languages 
other than English.
Although the costs and benefits to pregnant women arising 
from a vaccination program for the prevention of pertussis in 
the initial year were included, direct protection of the woman 
against pertussis disease may last for several years, and this 
might affect the cost-effectiveness of the program. Mothers 
play a central role in transmission of pertussis to infants and 
other household members.40 Thus, vaccination might prevent 
transmission within household contacts for several years after 
vaccination in pregnancy and potentially increase the cost-
effectiveness of this strategy.
Underreporting of pertussis cases may have affected the 
estimation of the true incidence and burden of pertussis dis-
ease, especially in older adults, and thus our model may have 
underestimated the cost-effectiveness of a program of vaccina-
tion during pregnancy. However, the effect of this under-
reporting is expected to be minimal, as pertussis in early 
infancy leads to severe disease that is recognized and reported 
in young infants, who are the primary target of protection fol-
lowing Tdap vaccination during pregnancy.
Our paper focuses on the effect of pertussis vaccination 
during pregnancy on the burden of pertussis disease in 
infants. Although the vaccine contains diphtheria and tetanus 
components, vaccination during pregnancy is not expected to 
have substantial beneficial or detrimental effects against teta-
nus and diphtheria diseases owing to the extremely low rates 
of disease in infants in Canada. In addition, higher antibody 
levels transferred to the infant after maternal Tdap vaccina-
tion may inhibit the infant’s response to subsequent vaccina-
tion to pertussis vaccines and other vaccines.41 Our model 
did not take into account the potential effect of this modula-
tion of the infant’s immune response, as its clinical signifi-
cance is unclear.
Our model assumed that the average program costs 
would be $2.50. Higher costs would have the incremental 
effect of reducing the threshold for the cost of the vaccine to 
be considered cost-effective. In addition, given that the 
acquisition cost of the vaccine is regarded as confidential 
information and is not publicly available in Canada, we 
adopted a price of $12.50, plus $4.50 in administrative costs. 
This value is similar to that used in published cost-
effectiveness analyses from other countries.36,39 Other associ-
ated costs were not included.
We recognize that, within Canada, the decision as to 
whether and how to implement a vaccination program is 
made at the provincial and territorial level, and such provin-
cial- and territorial-specific analyses should be done to inform 
local decision-making.
Conclusion
Based on a threshold of $50 000 per QALY gained, pertussis 
vaccination in pregnancy would be cost-effective if the acqui-
sition cost per vaccine were $14.03 or less. However, the 
applicability of our results for current and future policy deci-
sions depends on the incidence of pertussis disease, especially 
among infants less than 3 months of age, which is difficult to 
predict and can be province-specific.
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